April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Results of variable-dosing schedule with ranibizumab therapy in neovascular age-related macular degeneration in a clinical setting.
Author Affiliations & Notes
  • Michela Vinci
    Ophthalmology, University of Cagliari, Cagliari, Italy
  • Laura Porcu
    Ophthalmology, University of Cagliari, Cagliari, Italy
  • Maurizio Fossarello
    Ophthalmology, University of Cagliari, Cagliari, Italy
  • Footnotes
    Commercial Relationships Michela Vinci, None; Laura Porcu, None; Maurizio Fossarello, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3838. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michela Vinci, Laura Porcu, Maurizio Fossarello; Results of variable-dosing schedule with ranibizumab therapy in neovascular age-related macular degeneration in a clinical setting.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3838.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To describe the efficacy of therapy with ranibizumab (IVR) using as-needed dosing strategy or PRN after a single or 3 consecutive monthly injections of ranibizumab in patients with neovascular AMD.

Methods: We conducted a retrospective analysis of 40 eyes of 38 consecutive patients (mean age 76,5 years) with exudative age-related macular degeneration (AMD) treated for the first time by ranibizumab injection. On the basis of treatment, we identified two groups: 20 eyes were treated with a single IVR+ PRN, and 20 eyes with 3 IVR + PRN. All patients underwent a complete ophthalmological examination including Snellen visual acuity (VA) testing, fluorescein and indocyanine green retinal angiography and optical coherence tomography (OCT) at the visit baseline and during follow-up. Patients were followed for a maximum follow-up of 4 years.

Results: At the end of follow-up, in the eyes treated with 3 IVR+ PRN, the 94,7% showed an improvement in BCVA, and the 10,5% demonstrated worsening in BCVA, in comparison to the baseline values; while in the eyes treated with a single IVR + PRN, the 57,8% showed improvement in BCVA, the 21% demonstrated stable of BCVA, 26,3% revealed a worsening in BCVA, in comparison to the baseline values. The mean number of injections in the group treated with 3 IVR+PRN was 6,1± 1,2, while in the second group treated with 1 IVR+PRN was 4,7± 2,1, at the end of follow up.

Conclusions: Our results suggest that PRN treatment regimen may represent an effective strategy of treatment, preserving a significant visual improvement over time in patients with CNV secondary to AMD.

Keywords: 412 age-related macular degeneration • 453 choroid: neovascularization • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×